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Allelic variations in the genes involving the dopaminergic system, particularly the 
dopamine transporter (DAT1/SLC6A3), dopamine receptor 4 (DRD4) and Catecol-O-
Methyltransferase (COMT) genes have been associated with Attention Deficit 
Hyperactivity Disorder (AD/HD).  However, the results of these studies have been 
variable and inconclusive in part due to the inconsistencies of experimental and statistical 
methodologies, phenotypic heterogeneity, low penetrance of the genes implicated, and 
population stratification.  Genetic association studies based on linkage disequilibrium 
(LD) offer a promising approach to the study of common complex diseases.  This study 
characterized LD patterns in three human populations (CEU, YRI, CHB+JPT) in the 
three genes mentioned above and identified factors affecting the inconsistencies of 
genetic association studies in AD/HD.  We used the HapMap database and the Haploview 
program to evaluate linkage disequilibrium patterns of SNPs in these genes.  The 
regression results suggest that there is a trend toward poorer capturing of rare SNPs, 
which would mean lesser detection of AD/HD associations if rare SNPs were causative 
on these genes.  However, sparse sampling of tag SNPs in these genes (COMT and 
DAT1/SLC6A3) does not capture the other SNPs well and that a denser tag SNP set is 
needed to further test our results.  The significant reductions of the r2 in the other two 
populations relative to the CEU supports the contention that associations on these genes 
varies between populations and suggests that prior assessment of tag SNPs using the 
HapMap is an essential step in the design of genetic association studies.   
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CHAPTER I 
INTRODUCTION 
Attention deficit hyperactivity disorder (AD/HD; American Psychiatric 
Association, 1994) is characterized by chronic, pervasive, and developmentally 
inappropriate patterns of inattention, impulsivity, and/or hyperactivity (Anastopoulos, 
1999; Anastopoulus and Shelton, 2001).  It is a neurobehavioral disorder with a 
childhood onset and may persist in adulthood.  The prevalence of AD/HD may vary 
considerably depending on the diagnostic methods used and it is estimated to occur in 5-
10% school age children worldwide (Shastry, 2004).  It is also been found to be more 
frequent in boys than girls with a 3-4:1 ratio (Ogdie et al., 2003).  The Diagnostic and 
Statistical Manual of Mental Disorders IV (DSM-IV) of the American Psychiatric 
Association (APA) is the currently used diagnostic scheme for AD/HD (Heiser et al., 
2004).  It distinguishes among diagnostic subtypes characterized by predominantly 
inattentive (avoids tasks, forgetful, fails to finish tasks and usually loses things), 
predominantly hyperactive/impulsive (fidgety, talks a lot, blurts out answers to 
question and often interrupts), and the combined type.  Each subtype has nine 
observable behaviors and at least six of these have to be present in school or play 
activities for at least six months for diagnosis (Millichap, 1999).  These observable 
behaviors interfere with the individual’s peer and 
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family relationships as well as his/her performance in school and/or work.  Although 
the etiology of AD/HD is still unknown, current studies support the concept that 
AD/HD is a neurobehavioral disorder with multiple causes (Cooper and Bilton, 1999; 
Faraone and Biederman, 1998).  It has been strongly supported that AD/HD is highly 
heritable (Cooper and Bilton, 1999; Lopez, 1965; Millichap, 1999; Faraone et al., 
2005).   Genes involved in the neurotransmission such as neurotransmitters, its 
receptors and transporters are possible targets to further study the genetics AD/HD. 
(Biederman and Spencer, 1999).  Although candidate gene studies and genomic screen 
analyses provide reputable evidence on the genetic influence of AD/HD (Acosta et al., 
2003; Shastry, 2004;  DiMaio et al., 2003; Fisher et al., 2002; Ogdie et al., 2004;) their 
results are variable and there is limited progress in identifying the specific genetic 
factors that may contribute in the presentation of the disorder. 
The candidate gene studies suggest that multiple genes such as, DAT1/SLC6A3, 
DRD4, and COMT genes may be associated in AD/HD.    However, the results of these 
studies searching for specific variants on these genes are contradictory (Acosta et al., 
2003; DiMaio et al., 2003; Faraone et al., 2001)   The inconsistencies on these studies 
may be due to small contribution of a single polymorphism in the inheritance of AD/HD 
and genetic association studies may be at risk with spurious association (Pritchard et al., 
2000). The inability to replicate studies because of poor methodologies and issues in 
detecting association precludes a definitive conclusion on the genetics of AD/HD.   
Besides an accurate phenotype characterization, it is critical to have a well-developed 
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methodology (such as genetic marker selection, sampling and genotyping methods) in 
order to find true associations to better understand the genetics of complex disorders.  
Association studies are one of the study designs that can define the genetic 
correlates of common complex disorders such as AD/HD.  Although it is a 
straightforward method, it has been unsuccessful in identifying replicable associations for 
human complex diseases (Sullivan, 2007; Hirschhorn et al., 2002).  The International 
HapMap project is aimed to catalog millions of SNPs in the human genome and currently 
have genotype data in four human populations.  It is essential for any candidate gene 
association studies to evaluate SNPs of interest before genotyping.  Based on the idea that 
specific polymorphisms in the DNA sequence may reflect relationships between 
genotype and phenotype, these DNA sequence variations (such as SNPs) can be 
employed to infer the genetic basis of complex traits and/or predict the evolution of these 
variations (Chu et al., 2009); and that these variations are considered common (Frazer et 
al., 2009; Doris, 2002; Chen et al., 2006; Collins et al., 1999; Risch and Merikangas, 
1996; Lander, 1996).  In the presence of linkage disequilibrium (LD), polymorphisms 
(such as SNPs or haplotypes) that are in physical proximity to a polymorphism that 
causes the phenotype can show a difference in frequency between the affected and 
unaffected individuals (Barnes, 2006).  However, LD is generally affected by 
evolutionary factors such as population admixture and the age of the allele (Goldstein and 
Weale, 2001; Barnes, 2006).  Previous genetic association studies on the SLC6A3/DAT1 
and COMT genes have used 4-5 SNP haplotype to detect association for AD/HD 
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phenotypes using large sample populations (Genro et al., 2008; Halleland et al., 2008).  
These studies have shown that modest SNPs could be used to detect associations with a 
thorough consideration of the SNP selection and population samples.   
 
Specific Aims and Assumptions 
We used SNPs and their linkage disequilibrium (LD) patterns to evaluate single 
nucleotide genetic variation among these three candidate genes in three human 
populations.  The main purpose of this project is to evaluate the properties and predictive 
power of modest set of tag SNPs that are on the three candidate genes implicated in 
AD/HD, namely DAT-1/SLC6A3, DRD-4, and COMT genes on three populations 
genotyped on the HapMap database. (CEU – Utah residents with Northern and Western 
European ancestry from the CEPH (Centre d’Etude du Polymorphisme Humain) 
collection; YRI – Yoruba in Ibadan, Nigeria; and CHB+JPT – Han Chinese in Beijing, 
China + Japanese in Tokyo, Japan).  This project had three specific aims: 
1. Evaluate the practical usefulness of the HapMap database by obtaining 
genotyping data on the candidate genes and selecting up to three tag SNPs 
according to their minor allele frequency (MAF) using the CEU population. 
2. Use a low-throughput genotyping method (PCR-RFLP) to evaluate the 
selected SNPs on each gene using a panel of DNA samples in order to confirm 
the alleles called on the HapMap, follow their Mendelian inheritance pattern 
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on each gene.  Evaluate the limitations of this PCR-RFLP and compare it with 
a high-throughput method of genotyping (SNuPe). 
3. Test whether sparse sampling of SNPs contributes to inconsistent detection of 
potentially causative genetic variants among human populations.  Specifically, 
we hypothesized: 
a. The use of three or fewer SNPs per gene will not have consistently 
high LD (r2) with other SNPs detected.  This was tested by evaluating 
the highest r2 among the set assayed tag SNPs with each of the other 
HapMap SNPs in each gene. 
b. The detection of associations will be best for causative SNPs that are 
common, per the common-disease common-variant (CDCV) 
hypothesis.  This was tested by doing a regression of SNP-tag set r2 
values on MAF for each gene, with the expectation that the regression 
coefficient will be significantly positive. 
c. The tag SNPs selected in one population are less useful in other 
populations.  This was tested by comparing r2 of each identified SNP 
with the tag SNP set in the CEU with that in the other two populations.  
Significant reduction in the other two populations relative to the CEU 
would support our hypothesis. 
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If some SNPs show poor association with the assayed SNPs, if associations vary by 
population, or if potentially-causative rare alleles have poor associations with more 
common assayed SNP alleles, these factors could partially explain the inconsistent results 
of AD/HD association studies in the current literature.  This project will provide 
information to the broader genetics community on the advantages and disadvantages of 
SNP genotyping methods and tools for evaluating genetic markers that may help better 
design association studies.  These steps will further the study of genetic complex traits 
such as AD/HD and will advance our understanding of their pathogenesis. 
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CHAPTER II 
REVIEW OF THE LITERATURE 
AD/HD Phenotype and Comorbid Disorders 
Comorbidity refers to diseases or disorders that occur together, implying 
overlapping symptom patterns or, etiological commonalities, with implications for 
treatment, or 
increasing risk of 
negative outcomes 
(Lilienfeld et al, 1994).  
The presence of 
AD/HD in children 
increases their chances 
of having externalizing 
disorders such as 
oppositional defiant disorder (ODD) and conduct disorder (CD). They are also at risk 
for internalizing disorder such as depression and anxiety, and learning disabilities 
(Biederman et al, 1991).  Figure 1 shows the prevalence rate of these behavioral 
problems (Biederman, 2005).   
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Children with AD/HD can display variability in terms of the presence or 
absence of comorbid conditions.  AD/HD has been shown to be associated with an 
antisocial behavior trajectory that starts with oppositional defiant disorder (ODD) and 
is followed by conduct disorder (CD) (American Psychiatric Association, 1994).  
Jensen et al reviewed studies of AD/HD and its comorbid conditions.  They found that 
the available data suggest that comorbidity between AD/HD and CD/ODD is higher 
(42%-93%) than between AD/HD and internalizing disorder (13%-50.8%) (1997). A 
higher incidence of psychiatric disorder such as, ODD, CD, antisocial personality and 
criminal behavior, has been observed among parents and other biological relatives of 
children with ODD or CD.  Also, a review of twin studies found that there is higher 
concordance of CD/ODD among identical twins than fraternal twins (Altepeter and 
Korger, 1999).  These studies suggest a genetic component that may be involved in the 
development of ODD/CD.   
Oppositional Defiant Disorder (ODD) and Conduct disorder (CD) are often 
discussed together as antisocial behavior.  Although ODD and CD share common 
features of inattentive, impulsive, and overactive behaviors, these two are distinct from 
each other.  The primary features of ODD include patterns of negativistic, defiant, 
noncompliant and uncooperative behaviors.  In contrast, CD involves patterns of 
behavior in which the basic rights of others are violated.  According to the American 
Psychiatric Association (APA, 1994), CD is distinctive due to the recurrent violation 
of the rights of others and or the societal norms and rules (Altepeter and Korger, 1999). 
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Oppositional defiant disorder (ODD) is diagnosed in 5-25% of school age children 
(Altepeter and Korger, 1999). The DSM-IV of the APA (1994) categorizes ODD as a 
pattern of oppositional, negative, and hostile behavior that is observed at least six 
months or longer.  These behaviors can affect the individual’s social, occupational, and 
academic functioning. In addition, four or more behaviors such as losing one’s temper, 
arguing with adults, deliberately annoying others, blaming others for one’s misdeeds 
and being angry and resentful, are present during this period of time (Altepeter and 
Korger , 1999).   
Angold et al reviewed literature from community studies that used the DSM-III, 
DSM-III-R or DSM IV as a diagnostic guide and have reported rates of comorbidity 
between AD/HD and CD/ODD.  They have calculated the odds ratio (OR) and the 
confidence interval (CI).  Furthermore, they assess the variability between study 
effects by performing Chi-square tests for each OR.  They found that AD/HD-
CD/ODD comparison to be homogeneous.  The result of their meta-analysis suggests 
that the presence of AD/HD in children increases the odds of having ODD/CD by 7.7 – 
14.8 fold (Mean 10.7) with a 95% confidence interval (1999).  A two-year longitudinal 
study also supports the hypothesis that the hyperactive-impulsive behaviors seen in 
AD/HD influence the development of ODD (Burns and Walsh, 2002).  Although 
current literature suggests biological causes of ODD, they have not clarified whether 
genetic factors predispose some children with AD/HD to develop ODD.  The 
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phenotypic similarities of these comorbid disorders, particularly ODD with AD/HD, 
may suggest that the same genes may also be implicated.   
     
AD/HD and the Brain 
Cognitive research studies have observed the presence of a dysfunctional 
response system in the frontal lobe of the brain (where the neuropsychological 
mechanism is located), which causes the impulsive behavior seen in AD/HD (Cooper 
and Bilton, 1999).  The researchers characterize the affected individuals to be 
experiencing considerably greater problems in inhibiting or delaying response than 
most people.  In addition, the neuroimaging research studies have found that the 
impulsive behavior seems to line with the damages in the pre-frontal cortex of the 
brain (Cooper and Bilton, 1999).  Magnetic Resonance Imaging (MRI), 
Electrocephalographic examination (EEG) and Positron Emission Tomography (PET) 
are the procedures used to view the anatomy and activity of the brain. 
Furthermore, there have been eleven structural imaging studies of children, 
adolescents, and adults with AD/HD.  They have used computerized tomography (CT) 
and MRI.  Ten of these studies have found evidence of structural abnormalities in the 
brain of AD/HD probands.  Four of these studies specifically found abnormalities in 
the frontal cortex (Faraone and Biederman, 1998).  Comparatively, PET scans, which 
assess regional cerebral blood flow (rCBF) or glucose metabolism, show evidence for 
brain dysfunction among these AD/HD patients. Both structural and functional 
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neuroimaging studies suggest that the fronto-subcortical system in the brain is 
implicated in pathophysiology of attention deficit hyperactivity disorder (Frarone and 
Biederman, 1998).  Neuroimaging studies are ideal for testing hypotheses about the 
dysfunctional locus in the brain that might be implicated in AD/HD.  These studies 
directly assess the brain structure and function.  However, they are expensive and are 
only applied to small samples.  This will affect the statistical power of these studies 
and may not give a definitive conclusion on the pathology of AD/HD (Faraone and 
Biederman, 1998). Nonetheless, these studies provide increasing support for the 
concept of AD/HD as a brain based disorder that has a biological basis. 
 
Heritability of AD/HD 
 Many research studies support the presence of a genetic component of AD/HD 
(Cooper and Bilton, 1999; Lopez, 1965; Millichap, 1999, Faraone et al., 2005).  These 
studies include family studies which have shown that the disorder is more common in 
biological relatives of children with AD/HD than it is in biological relatives of children 
without AD/HD (Cooper and Bilton, 1999). Furthermore, twin studies provide direct 
evidence on the heritability of AD/HD.  Lopez (1965) studied hyperactivity in twins.  
Among the ten pairs of twins in which (at least one exhibits the hyperactive subtype), 
all four pairs of MZ (monozygotic), all boys, were concordant (i.e. both affected).  
Only one of the six DZ (dizygotic) showed concordance (Millichap, 1999).  Faraone et 
al (2005) have compiled heritability estimates from 20 twin studies from the United 
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States, Australia, Scandinavia, and the European Union.  The heritability estimate is 
found to be 76%, and suggests that AD/HD is among the most heritable of psychiatric 
disorders. Figure 2 is a summary of these studies. These studies provide strong 
evidence for a genetic basis contributing to the behavioral symptoms of AD/HD. 
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Genome-wide Scans and AD/HD 
 A complementary strategy for pinpointing genetic risk factors involved in 
AD/HD susceptibility is to perform a systematic genome wide scan of affected 
subjects.  A genome-wide scan by Fisher et al (2002) found that 17p11 (maximum 
LOD Score, MLS=2.98) region could harbor risk genes for AD/HD.  The 
chromosomal regions 5p12, 10q26, 12q23, and 16p13 are also of interest.  In addition, 
a fine mapping study by Smalley et al (2002), using same sample as Fisher et al, 
suggests the 16p13 (MLS=4.2) region may contain possible genes contributing to 
AD/HD symptoms.  Furthermore, Ogdie et al extended the sample size used by Fisher 
et al and performed a fine mapping study.  They found that 6q12 (MLS=3.30), 17p11 
(MLS 3.63) and 5p13 (MLS=2.25) are likely to harbor susceptibility genes for 
AD/HD.  Interestingly, the regions 16p13, 17p11 and 5p13 are also regions of interest 
in autism (Ogdie eat al, 2004; Smalley et al., 2002). These studies serve as foundation 
for subsequent investigations using association methods to detect risk genes of 
moderate effect size. 
  
Candidate Genes and AD/HD 
 Attention deficit and hyperactivity disorder, like most psychiatric disorders, is 
considered to be genetically complex.  Its phenotype ranges from mildly to severely 
affected.  The disorder exhibits familial clustering, but its transmission does not clearly 
show a classical Mendelian segregation (Acosta et al., 2003).  Most molecular genetic 
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studies of AD/HD center on the candidate gene approach.  Through observations based 
on using psychostimulant drugs, animal models and by theoretical considerations, the 
genes in the dopaminergic, serotinergic, and adrenergic systems are possible targets 
(Shastry, 2004). There have been a number of cumulative studies that have found 
evidence supporting the presence of major genes that may be implicated to the 
susceptibility of AD/HD.  Researchers have used different genetic approaches such as 
family-based and case-control studies to test for association and/or linkage to these 
candidate genes.  However, these studies show variable results.  Some studies found 
linkage while others did not (Acosta et.al. 2003).  Therefore, it is important to do 
further testing of association on susceptibility genes and dissect each gene for its small 
genetic effect and possibly its interactions with other candidate genes.  There are eight 
genes implicated in the dopaminergic system, which includes its receptors, transporters 
and the metabolizing enzymes. 
  
The DAT1/SLCA3 Gene 
Gene knock-out mice experiments show that a mouse that lacks the dopamine 
transporter gene (DAT1 or solute carrier family 6, member 3 (SLC6A3)) has increased 
locomotor activity (Giros et al, 1996).  The disruption of DAT1 gene inhibits the 
proper delivery of dopamine.  This makes the knock-out mice display behavior such as 
hyperactivity like that observed in AD/HD.  Methylphenidate, the major 
pharmacological treatment of AD/HD, and other psychostimulant drugs, target the 
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dopamine transporter and increase synaptic levels of dopamine.  These drugs help 
control the symptoms seen in AD/HD (DiMaio et al, 2003). 
DAT1/SLC6A has been localized to chromosome 5p15.3.  DiMaio et al (2003) 
compiled studies of association between the 480-bp VNTR (variable number tandem 
repeat) or 10R allele of the dopamine transporter gene and AD/HD (Table 1). Most of 
these studies have used case-control and family based association designs.  They used  
 
 
statistical analysis, such as HHRR test (Haplotype based Haplotype Relative Risk and 
TDT (Transmission Disequilibrium Test). Two out of the six studies using the TDT 
statistic have identified linkage and two out of the three studies using the HHRR test 
also found linkage.  The causes of the discrepancies among these studies are unknown, 
but linkage in the TDT studies may be difficult to detect if sample sizes are insufficient 
in each group.  Consequently, Ouelle-Morin et al did not find association in the VNTR 
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region of this gene with AD/HD related phenotypes in a Canadian population-based 
sample of same-age twins but found positive association for the rs27072 
polymorphism (2007).  This suggests that other polymorphisms in this gene may exist 
as possible markers for AD/HD and different polymorphisms may be associated in 
different population groups.  However, due to the alteration of dopamine transporter 
regulation by the psychostimulant drugs and its contribution to the AD/HD symptom 
relief, DAT1/SLC6A3 is still a good candidate gene for AD/HD. 
 
The DRD4 Gene 
The dopamine receptor 4 gene (DRD4) is in chromosome 11p15.5.   This gene 
is one of the five that code for receptor proteins for the dopamine neurotransmitter. Its 
diversity is primarily due to the length and single-nucleotide polymorphism (SNP) 
variation in a 48-bp VNTR (variable number of tandem repeat) in exon 3 of the gene.  
This region encodes the third intracellular loop of this receptor (Chang et al., 1996).  
There are about 11 DRD4 VNTR repeat alleles found worldwide in the human 
population.  The 4-, 7-, and 2- repeat alleles are the most prevalent (Ding et al., 2002; 
Wang et al., 2004).  The 7-repeat allele has been of interest because of its high 
frequency in the Americas (where AD/HD is more prevalent), but its frequency is low 
in Asian populations where AD/HD has low prevalence (Grady et al., 2003; Leung et 
al., 1996).  
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DRD4 is also a good candidate gene because of the pharmacological treatments 
(such as amphetamine, methylphenidate, and pemoline) for AD/HD that target 
primarily the dopamine system (Swanson et al, 1998).  It is observed that DRD4 
mRNA is localized in the frontal and prefrontal cortical regions of the brain, suggested 
regions where attention is regulated.  Also, this gene is associated with the novelty 
seeking personality that may be related to the expression of behaviors seen in AD/HD 
(Swanson et al, 1998).  DRD4 gene-knockout mice show reduce novelty seeking 
behavior and increased locomotor sensitivity to ethanol, cocaine, and 
methylamphetamine (Bobb et al, 2004).  
A study using a family-based approach provides further evidence that the 
DRD4 gene is associated with a refined phenotype of AD/HD (Swanson et al., 1998).  
Faraone et al. (2001) used meta-analysis of both case-control (8 studies) and family-
based (14 studies) association studies between AD/HD and the 7R allele of the 48bp 
VNTR polymorphism.  Five of the eight case-control studies found positive 
association with a combined estimate of OR (odds of ratio) 1.9.  In the family based 
studies, nine studies showed positive linkage with a combined estimate OR of 1.4. 
Their meta-analysis study highly support the association of 7R allele of the DRD4 gene 
with AD/HD. In addition, DiMaio et al. (2003) reviewed association studies between 
AD/HD and DRD4 7-repeat allele (Table 2).  These studies either used case-control 
association or family-based association but reported variable results.  Furthermore, a 
study found that volumetric abnormalities in the dorsolateral prefrontal cortex and 
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cerebellum may represent an intermediate neuroanatomical phenotype between DRD4 
risk alleles and the clinical expression of adult AD/HD (Monuteaux et al, 2008).  This 
makes the DRD4 gene a good candidate for AD/HD, and perhaps other polymorphisms 
are also implicated in the presentation of the disorder. 
   
The COMT Gene 
  The Catechol-O-Methyltransferase (COMT) gene is an attractive candidate for 
AD/HD because the enzyme encoded by this gene is involved in the degradation of 
dopamine, norepinephrine, and epinephrine (Faraone et al., 2005).  It is not as well 
studied as the DAT1 and DRD4 genes. The gene that encodes for the COMT enzyme 
has been localized to the chromosomal region 22q11.1-q11.2.  Some studies have 
observed the involvement of COMT in several AD/HD-related behaviors, substance 
abuse cases and novelty-seeking personality (Bobb et al., 2004).  DiMaio et al. also 
compiled association studies between AD/HD and COMT polymorphisms (Table 3), 
but only one of these studies shows evidence of linkage (2003).  Due to the 
inconsistent results, further molecular studies in defining markers (such as SNPs) on 
this gene are needed in order to test for association with AD/HD. 
In addition, the COMT gene contains functional polymorphisms such as the 
Val158Met, rs4680 which can affect the activity of the enzyme to process dopamine in 
the prefrontal cortex (Lachman et al., 1996; Chen et al., 2004).  A study on an ethnically 
homogenous 
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and Caucasian origin sample population found that the Val allele on this SNP is more 
frequent in AD/HD group than in the control population (Kereszturi et al., 2008).  In 
addition, the Val allele (homozygous) was found to be associated with AD/HD 
(predominantly inattentive) subjects with comorbid ODD in a Chinese population sample 
group.  They also looked into variants on the MAOA gene but found no positive 
association, suggesting that there is no epistatic effect of MAOA to the COMT gene (Qian 
et al, 2009). 
  
 
Genetic Association Studies, SNPs as Genetic Markers, Common-Disease Common-
Variant (CDCV) Hypothesis and Linkage Disequilibrium 
Genetic association studies are one of the study designs that can define the genetic 
correlates of complex disorders such as AD/HD.  Although it is a straightforward 
method, it has been unsuccessful in identifying replicable associations for human 
complex diseases (Sullivan, 2007; Hirshhorn et al., 2002).  Association studies test for a 
particular genetic marker that could potentially be implicated with the disease of interest 
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across the population rather than within families, which allow these studies better power 
to detect the effects of common variants compared to linkage studies (Hirschhorn, 2005; 
Risch, 1990; Risch and Merikangas, 1996).  Efficient recognition of genetic variations 
among individuals in different populations is an essential step for a successful association 
study to further understand the genetics of AD/HD and may help resolve the varying 
results of these studies and/or in any other association studies (DiMaio et al, 2003; 
Cardon and Bell, 2001).  The completion of the Human Genome Project has led to the 
development of numerous highly polymorphic markers (microsatellites and SNPs).  
Genetic markers are defined as any polymorphic Mendelian character that can be used to 
follow a chromosomal segment through a pedigree.  A good genetic marker has to be 
polymorphic or have a high heterozygosity index, meaning that a randomly selected 
individual in a given population has a considerable chance of being heterozygous for that 
polymorphism of interest (Strachan and Read, 2004).   
SNPs are the preferred markers for association studies because they are 
estimated to occur at a frequency of 1in every 1,000 bases on average in the human 
genome (Syvanen, 2001).  Their abundance helps define linkage disequilibrium islands 
and can be scored through various high-throughput methods (Sobrino et al, 2004).  
Figure 3 shows steps of SNP genotyping.  They are less mutable than microsatellite 
markers and common SNPs could be found in different populations, but their allele 
frequencies may vary (Romualdi et al, 2002).   With the assumption that the 
susceptibility to common diseases is mainly determined by common ancestral DNA 
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variants, a more stable marker like SNPs should be more valuable for identifying 
ancestral haplotypes or sets of SNP alleles occurring together on a chromosome 
(Strachan and Read, 2004).  This has led to the common-disease common-variant 
(CDCV) hypothesis which argues that the genetic variation underlying susceptibility to 
common heritable disease/trait existed within the founding population of contemporary 
human population and that these genetic variants have escaped selective pressure and 
have small to modest effect on the disease/trait (Doris, 2002; Chen et al., 2007; Collins 
et al., 1999; Risch and Merikangas, 1996; Lander, 1996).  Furthermore, four arguments 
support the CDCV hypothesis (Hirshhorn, 2005; Lohmueller et al., 2003; Reich and 
Lander, 2001): 
1.  Common diseases/traits are not as evolutionarily disadvantageous as 
single-gene diseases/trait.  Monogenic traits usually cause early death 
and/or limit reproductive capability. 
2. Variants for monogenic traits are highly penetrant whereas multiple variants 
are often implicated in common complex traits.  This decreases the selective 
pressure of the genetic variants on common traits. 
3. Monogenic traits are rare and polygenic traits are more common.  This leads 
to the hypothesis that the causal genetic variants for common complex traits 
should have a high frequency in the population due to demographic history 
of the human population. 
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4. Empirical experiments supports that common genetic variants contribute to 
the risk of common/complex traits. 
These assumptions may also explain the varying results found in the association 
studies found on AD/HD (DiMaio et al., 2003; Acosta et al., 2003; Hirschhorn et al., 
2002). 
 Genetic association studies are based on linkage disequilibrium (LD) between 
marker alleles and causative alleles for a trait or disease. LD is defined as the association 
of alleles on a chromosome.  It is a measurement of the difference between the combined 
observed allele frequencies of a two-locus allelic combination and the product of their 
individual allele frequencies (expected frequencies).   A low LD means that alleles at the 
two loci tend to be randomly associated.  Human variation studies have shown that 
nearby SNPs typically show high LD levels and these form highly variable segments 
(haplotypes) in the genome (Gabriel et al, 2002).  The linkage disequilibrium pattern of 
SNPs enables the capture of common genetic variants by genotyping subsets of SNPs 
(‘tag’ SNPs, Haplotype-tagging) across the genes of interests or chromosomes implicated 
in a disease or disorder (Haiman and Stram, 2008).  The knowledge of LD and common 
haploytpe patterns in disease association can improve the cost effectiveness of these 
studies because it guides in the selection of informative `tag` SNPs (Bakker et al, 2005).  
The International HapMap Consortium uses D’ and r2 as the main statistical measures for 
LD (Barnes, 2006).  The calculation of LD is derived from consideration of two loci A 
(A, a alleles) and B (B, b alleles) and four possible haplotypes with their allele 
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frequencies as p.  D’ = (pAB – pApB)/Dmax; Dmax is the maximum value of |pAB-pApB| 
possible allele frequencies; D = pABpab-paB.  If D’=1 then the two SNPs have not been 
separated by recombination during the history of the sample.  The D’ measurement is 
useful within studies but not between different populations (Barnes, 2006; Pritchard and 
Przeworski, 2001; Mueller, 2004).   r2 or ∆2 = (pAB-pApB)2/(pApapBpb) (Starchan and Read, 
2004).  r2 is the preferred choice measure of LD when the focus is on the predictability of 
one polymorphism given the other and therefore it is often used in power studies for 
genetic association study designs (Chen et al., 2006).  The inverse value of r2, (1/ r2) 
provides a practical estimate of magnitude by which the sample size must be increased in 
a study design to detect association between the genetic marker and the disease/trait of 
interest (Pritchard and Przeworski, 2001).  The International HapMap consortium has 
provided a public database of common variation in the human genome, particularly 
SNPs.  They have genotyped 269 DNA samples from four different populations (CEU, 
YRI, and CHB+JPT) and characterized LD patterns to provide recombination hotspots in 
the human genome (The International HapMap Consortium, 2005).  This has become an 
essential resource that can guide study designs (SNP selection and defining LD patterns 
and haplotypes) for future genetic association studies.  
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CHAPTER III 
MATERIALS AND METHODS 
SNP Genotyping: SNuPe   
A panel of DNA samples was used to optimize this genotyping method.  The 
selection of SNPs for DAT1/SLC6A3, DRD4 and COMT genes was gathered from 
database searches through Ensemble, dbSNP, HGbase, and TSC (Nelson, personal 
communication, data not shown).  These database searches allowed us to identify 
SNPs in the candidate genes and derive the primary sequence of the SNP region for 
each gene.  For this method, primers were designed to amplify the region containing 
the SNP of interest using Primer 3 software (http://frodo.wi.mit.edu/).  The PCR 
products were approximately 300 base pairs (bp).  After PCR amplification, the SNP in 
that region was assayed using a single base extension (SNuPe) reaction.  SNuPe 
involved binding an oligonucleotide primer immediately 5’ of the SNP and then 
extending it by a single base using differently fluorescently-labeled dideoxy 
terminators (ddNTPs) for each base; this labeled the candidate SNP gene site with 
flurochromes.  The SNPs were then scored by capillary gel electrophoresis on a 
MegaBace 500 sequencer.  The MegaBace SNuPe genotyping kits and protocols by 
Amersham Biosciences were followed accordingly (Appendices A-C).
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DNA Samples for PCR-RFLP 
Five family trio DNA samples were ordered from National Institute of General 
Medical Science (NIGMS) DNA Bank.  These were used to assess the Mendelian 
inheritance for each SNP and give information about the polymorphism value for these 
SNPs.  Table 4 shows sample information.  The DNA samples were quantified using the 
Nanodrop Spectrophometer ND1000. 
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SNP Selection 
 The SNPs (tag SNPs) selected did not have a particular functional 
polymorphism that caused a change in the amino acid sequence.  SNPs were first 
screened according to their minor allele frequencies (MAF, at least 0.2 and greater if 
possible), and unique polymorphism patterns on the CEU (Centre d’Etude du 
Polymorphisme Humain, individuals from Utah, USA with European descent) 
population.  We utilized the genotype data available on this population in the HapMap 
database.  SNPs were then further screened according to the availability of restriction 
enzymes.  Three SNPs were selected for COMT (rs737866, rs5993882, and rs4633) 
and DAT1/SLC6A3 (rs10052016, rs1042098, and rs463379) genes.  However, there 
were only two SNPs genotyped on the DRD4 gene on the HapMap database (accessed 
August 2008) and there were no restriction enzymes available for these SNPs.  The two 
SNPs assayed in the DRD4 gene were selected based on the heterozygosity score on the 
NCBI website and/or their location in the gene (Table 5).  A study using a common 5-
SNP (rs2550948, rs11564750, rs261759, rs2652511, rs2975223) haplotype located in the 
5’ region of SLC6A3/DAT1 detected association with AD/HD (243 families with 186 
parent proband trios and 57 parent-child duos, Brazil population) (Genro et al., 2008).  In 
addition, using a  4-SNP haplotype (rs6269, rs4633, rs4818, rs5680) on the COMT gene 
showed a trend for association with their hyperactivity/impulsivity sample group (435 
probands and 245 controls from all parts of  Norway) (Halleland et al., 2008).  Our SNP 
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selection method (using 2-3 SNPs as tags) was thus not as robust as those used in these 
recent studies.  
  
SNP-Genotyping:  PCR-RFLP 
The Primer 3 program was used to design primers to amplify the region 
containing the SNPs of interest.  The FASTA sequences (from NCBI) were used as the 
input for the program.  The same sequences were used on the NEBcutter website to 
select for restriction enzymes and made sure that the restriction enzymes cut 
specifically at the SNPs and not at other sites within the PCR product. Table 5 
summarizes the tag SNPs on each gene, restriction enzymes, primer sets and their 
annealing temperatures.  
We used 25 nanograms (ng) of DNA per sample to perform PCR. A 10x PCR 
buffer (Promega), left and right primers, MgCl2, dNTPs and deionized water were added 
accordingly with a twenty five microliter (25µl) total volume.  A thermal cycling 
protocol was used adjusting the denaturation, primer annealing and DNA synthesis 
temperatures (see Appendix D).  PCR products were confirmed by running gel 
electrophoresis using ethidium bromide treated agarose gels (80-90 volts for 1-2 hrs).  
After the presence of the product was confirmed, 10 µl of the PCR product was used for 
PCR-RFLP.  The incubation temperature of PCR-RFLP was based on the information 
that came with the restriction enzyme.  The PCR-RFLP products were electrophoresed on 
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ethidium bromide treated agarose gel with the same voltage.  SNP genotypes were called 
according to their banding patterns (Table 5). 
  
‘Tag’ SNPs Analysis 
 The Haploview software was used to assess the linkage disequilibrium scores for 
the SNPs selected on each gene (http://www.broad.mit.edu/mpg/haploview/).  We used 
the assayed SNPs (PCR-RFLP) as our ‘tag’ SNPs and compared the LD values 
(expressed as the squared correlation of allelic occurrences, r2) of this set of SNPs with 
all other identified SNPs in the three populations (CEU, YRI and CHB+JPT).  LD values 
were evaluated using the Haploview tagger program and setting the r2 threshold to 0.01 
in order to capture all the SNPs in each gene. The Haploview (Tagger) assigned the SNPs 
to any of the tag SNPs where they had the highest r2 value.  A Wilcoxon Signed Ranks 
Test was used to compare the distribution of LD values (r2) in the CEU population from 
which the tag SNPs were initially chosen to those in the other populations.  A regression 
analysis was used to test the relationship of the SNPs’ r2 values with their MAF values 
within each population and plot their distribution (SPSS program). 
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CHAPTER IV 
RESULTS 
SNP Genotyping:  SNuPe  
With the DNA samples provided, we ran PCR using the DRD4 gene primer sets 
with 25 nanograms (ng) of DNA.  We used two different concentrations of MgCl2 for 
comparison and adjusted the annealing temperatures accordingly. A 50-Enhanced PCR 
cycling temperature program (courtesy of Li-cor Biotechnology) was used to amplify 
the regions containing the SNPs of interest.  PCR products were electrophrosed on 
ethidium bromide treated agarose gels. Figure 4 shows that using a lesser concentration 
of MgCl2 (2.5mM) was better for these primer sets.  We then used the same protocols 
for the primer sets on DAT-1/SLC6A3 and COMT genes (data not shown).  These 
results showed that there is an ~80% success rate of amplifying PCR products (regions 
of interest) on each gene using this PCR protocol, and the 50 Enhanced thermal 
cycling program (See Appendix for protocols).  Robust amplification of these regions 
is essential for the downstream steps involved in SNP genotyping assays. 
After amplifying these regions in each gene, the SNuPe genotyping kits and 
protocols (provided by Amersham Biosciences) were followed accordingly.  The 
products were run on a Megabace 500 Sequencer which showed  
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electropherogram peaks of the SNPs and provided quality scores indicating the 
confidence of the SNP calls.  A quality score of 5 to 10 was suggested to be reliable by 
Amersham Biosciences.  During the final spin (clean-up step, sephadex plate) of 
SNuPe products, some of the samples were not recovered, which may have resulted in 
our poor quality scores.  An alcohol clean up method was used, but the SNuPe results 
were worse than with the sephadex clean up method.  After several trials of making 
sephadex plates and using water to optimize this clean up step, I was able to recover 
90% of my samples.  This is yet to be tested on real samples.  Furthermore, in order to 
confirm the SNPs that are read by the MegaBACE sequencer, I sequenced the regions 
of interest using a Licor DNA Analyzer protocols (provided by Li-Cor Biotechnology).  
The sequencing results showed the same allele reading on the MegaBACE. Table 6 
shows our sequencing results compared to the SNuPe results (see Appendices A-C for 
protocol information).
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SNP Genotyping: PCR-RFLP 
 Due to the unreliability of the SNuPe assay and budget issues, we adopted to the 
PCR-RFLP approach to assay SNPs.  The candidate SNPs selected for the SNuPe assay 
did not have restriction enzymes, therefore, we chose SNPs accordingly.  This was the 
limiting factor for this method (See methods for selecting tag SNPs).  Some results of the 
PCR-RFLP gels were unclear due to incomplete digestion of the PCR products by the 
restriction enzymes and clarity of the bands on the agarose gels.  However comparing 
the allele calls from the HapMap database and the inference of Mendelian allelic 
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inheritance of each family trio helped in the identification of the right genotype for 
each individual.  Consequently, the primer sets for one SNP (rs9364643) on the DRD4 
gene did not amplify the specific product.  Multiple bands were produced and therefore 
we did not proceed with PCR-RFLP.  Perhaps another genotyping method may be 
needed to assay this SNP.  Figures 5, 6 and 7 show PCR-RLFP results for COMT gene. 
The PCR-RFLP results for the DAT1/SLC6A3 and DRD4 genes were not included.  
Tables 7 (COMT) and 8 (SLC6A3/DAT1) show the SNP genotype calls on our PCR-
RFLP results and HapMap genotype calls for selected individuals. 
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Allele Frequency and Linkage Disequilibrium 
We evaluated the performance of HapMap tag SNPs from the CEU population by 
comparing allele frequencies and LD patterns to the YRI and CHB+JPT populations.  
These comparisons helped us assess our hypothesis that sparse sampling of SNPs 
contributes to inconsistent detection of potentially causative genetic variants among 
human populations. In general, our results show differences on the SNPs minor allele 
frequency distribution in each gene on the different populations; and some SNPs 
(captured) have strong r2 with the tag SNPs however, most of them have low r2 with the 
tag SNPs.  These observations may have limited our power to detect trait association with 
potential causative variants.  Figure 8 shows the minor allele frequency distribution of the 
tag SNPs and captured SNPs on the COMT gene amongst the three populations.  Figure 9 
shows the MAF distribution on the DAT1/SLC6A3 using 3 tag SNPs and on two 
populations only since there was no data on the HapMap database for one of the tag SNPs 
(rs463379) on the CHB+JPT populations.  A two tag SNPs analysis was then executed 
using 2 tag SNPs (rs1042098, rs10052016) to evaluate the MAF patterns of the three 
populations (Figure 10).  Although, allele frequencies of SNPs (markers) in each 
population represent only sample estimates of some underlying population parameters 
(Mueller, 2004), their values have an effect on the calculation of LD.  Figures 11, 12 and 
13 show the LD (r2) distributions of the captured SNPs on these two genes in each 
population. 
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MAF and LD (r2) relationship 
 The relationship between MAF and r2 of captured SNPs with the tag SNPs for 
each population on each gene was estimated using a regression analysis.  Overall, our 
analysis showed a positive relationship between r2 and MAF (i.e. a tag SNP captures a  
SNP that is close or equal to its MAF, the closer the tag SNPs (MAF) the higher their LD 
on a particular SNP).  This is evident with the results from the COMT gene and 
DAT1/SLC6A3 (3 tag SNPs) analysis (Figures 14 and 15).  However, this relationship 
may have been confounded by the tendency of some captured SNPs to have high r2 (close 
to 1) with the tag SNPs of similar MAF on the DAT1/SLC6A3 gene.  The data for 
DAT1/SLC6A3 gene using 2 tag SNPs may suggest that using more tag SNPs are more 
efficient to better capture LD with the remaining SNPs (Figure 16).  Table 9 COMT gene, 
Table 10 SLC6A3/DAT1 gene (3 tag SNPs) and Table 11 SLC6A3/DAT1 gene (2 tag 
SNPs) show MAF and r2 values for all the SNPs in each gene in each population. Our 
ANOVA tests (one-tailed) showed that in the COMT gene there is a marginally 
significant regression effect of r2 on MAF for the CEU population (p=0.024), but not for 
the YRI population (p=0.08) and for CHB+JPT (p=0.173).  Even though these tag SNPs 
captured the same number of SNPs in each population, the inconsistent trends are 
probably due in part to the different MAFs of the tag SNPs amongst the three 
populations.  In summary, Figure 14 shows the relationship plot between MAF and r2 for 
each population on the COMT gene and Table 9 shows the r2 and MAF values.  The MAF 
and r2 patterns of all the populations on this gene seemed dispersed but the linear 
regressions showed a positive slope.  For the DAT1/SLC6A3 gene, using 3 tag SNPs 
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showed significant effect of MAF on r2 for each of the populations (CEU, p=0.003; YRI, 
p=0.0005).   The regression patterns showed a positive slope, but clusters of captured 
SNPs that have an absolute LD (r2 = 1) are apparent in both populations (Figure 15, 
Table 10).   However, there was no significant effect of r2 on MAF using the 2 tag SNPs 
(that can be scored in all populations) analysis on this gene (CEU, p=0.390; YRI, 
p=0.241; CHB_JPT, p=0.002).  The CEU and YRI regressions showed positive slope, but 
no significant effect of r2 on MAF may be due to the clusters of SNPs with high r2.  The 
significant regression results on the CHB+JPT population (using two tag SNPs) do not 
support the hypothesized relationship because of the scattered distribution of the plots 
and the slope is negative (Figure 16, Table 11). 
    
Linkage Disequilibrium (r2) Patterns 
We measured the LD structure for the captured SNPs using the tag SNPs for each 
gene.  We used the highest r2 value between each SNP and the tag SNPs as our measure 
for LD and compared them amongst populations.  We used the Wilcoxon Sign Test (one-
tailed test) because we were only interested in the hypothesis that the r2 values are lower 
on the in the YRI and CHB+JPT populations when each is compared to the CEU 
population.  Our tests showed a significant difference in r2 in the COMT gene between 
CEU and YRI (p=0.0265); and a suggestive difference between CEU and CHB+JPT 
populations (p=0.07).  Figure 11 shows the r2 distribution for each population on the 
COMT gene.  On the DAT1/SLC6A3 gene using three tag SNPs, there was significant 
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difference between CEU vs. YRI, p=0.022.  Figure 12 shows the r2 distribution for each 
population.  In addition, using 2 tag SNPs in this gene also showed the same trend, CEU 
vs. YRI ( p=0.018); and for CEU vs. CHB_JPT, (p=0.040).  The key differences between 
the data sets for this gene (2 or 3 tag SNPs) were not merely the number of tag SNPs but 
also the number of SNPs shared among CEU and YRI populations only versus those 
shared among all three populations. Figure 13 shows the r2 distribution for each 
population. 
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CHAPTER V 
DISCUSSION 
Utilizing the HapMap Database 
We evaluated the practical usefulness of the HapMap database by obtaining 
genotyping data on the three candidate genes (COMT, DAT1/SLC6A3 and DRD4) using 
the CEU population as reference.  Due to costs and limitations of our genotyping method, 
we were unable to select 3 SNPs per LD block as envisioned for the use of the HapMap 
data.  We selected tag SNPs (2-3 per gene) that have fairly good minor allele frequencies 
(0.2 -0.47, Tables 5, 9 and 10) and have polymorphism patterns distinct from each other.  
The database is user-friendly and provides detailed information on MAF and LD patterns 
of SNPs that facilitates in the design for genetic association studies in identifying 
common genetic variants that may contribute to complex common disorders.  Currently, 
the International HapMap consortium provides a catalog of common genetic variations 
(SNPs) in four different populations (CEU, YRI, CHB+JPT) (The International HapMap 
Consortium, 2005; accessed October, 2008).  The analysis of common SNPs is currently 
the approach to study the genetic bases of complex diseases or traits.  This approach may 
allow us to identify risk factors and find genetic markers (on specific gene products) that 
affect the biological presentation of the diseases/traits of interest (Gonzalez-Niera, et al., 
2006).  However, the transferability of common SNPs (tag SNPs) amongst the human
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population is still unclear.  The database is continually being updated and still is 
incomplete as we have encountered with the DRD4 gene in which there were only two 
genotyped SNPs on this population and were not informative (accessed October 2008).  
The database once complete or updated will provide preliminary data of the LD patterns 
of SNPs that may help an investigator tailor markers for its particular sample population 
for an effective association study design. 
  
SNP Genotyping Assays 
 One of the essential components of any genetic association studies is generating 
genotypes for the genetic markers, particularly SNPs, to test for association with the 
common trait of interest.  We evaluated two SNP genotyping methodologies namely, 
PCR-RLFP and SNuPe.  PCR is the first step for any genotyping methods (Chen and 
Sullivan, 2003).  The PCR assay can be affected by several factors such as primer 
designs, thermal cycling (Tm of the primers) and reagents on the PCR.  We have used the 
Primer 3 program (available online) to design primers for the two SNP genotyping 
methods (primer designs for the SNuPe by Sara Nelson) and selected primer pairs that are 
of similar melting temperatures.  A touch-down PCR (50 Enhanced, see Appendices A-
C) thermal cycling program was used to amplify the products for the SNuPe method and 
then visualize with ethidium bromide treated agarose gels.  Our results showed that 
MgCl2 is an important factor in PCR assays.  It is suggested that lower concentration of 
Mg2+ were desirable when the fidelity of DNA synthesis is essential.  There is a 
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reciprocal relationship of Mg2+ ions and dNTPs, therefore a change in the ion 
concentration usually requires similar modification to the amount of dNTPs (Vance 
and Othmane, 1998).  The other reagents were added accordingly by our laboratory 
protocols and other references (Vance and Othmane, 1998; Starchan and Read, 2004).  
Optimization of PCR assays by considering these factors will help in the downstream 
steps for an accurate SNP calls on any SNP genotyping assay. 
PCR-RFLP SNP genotyping assay is based on a single base pair change that 
creates a cutting site for a specific restriction enzyme (Vance and Othmane, 1998).  Our 
PCR products were digested with their specific enzymes and ran on an ethidium bromide 
treated agarose gels (Appendix D for specific protocols).  Although this method of 
genotyping is straightforward and does not require the purchase of an expensive 
equipment to detect the SNP alleles, it has its own limitations.  We had encountered 
difficulties in interpreting the banding patterns of our PCR-RFLP gels due to the 
incomplete digestion by the restriction enzymes, which thus may give a false genotype 
read.  Due to the known inheritance pattern of our family trios and comparing our SNP 
genotype data on the HapMap database we were able to confirm the genotypes of our 
individual samples.  We were also limited with the tag SNPs selection because there were 
no restriction enzymes available for several of the SNPs on each gene and there were no 
enzymes available for the SNPs that were genotyped on the HapMap database for DRD4 
gene.  For a larger sample study a high-throughput efficient genotyping method such as 
SNuPe assay is a better approach as it would allow us to type more SNPs and thus help in 
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selecting a denser ‘tag’ SNPs to better capture LD patterns on these candidate genes.  
However, optimization of methodologies is critical in order to generate reliable 
genotypes.  For our single base extension assay (SNuPe) the SNP is identified by using a 
third oligonucleotide primer to the 3’ end of the SNP of interest (added to the PCR 
product).  This primer recognizes the SNP of interest and labeled with fluorochromes for 
detection.  SNPs were then scored by capillary gel electrophoresis on a MegaBace 500 
sequencer machine (Protocols followed in suggestion by Amersham Biosciences).  Our 
SNuPe genotype results were not robust and of low quality as probably resulted from the 
low recovery of products during the final spin of the clean-up step (see Appendix); and 
even with alternative clean-up method did not improve the quality of the genotypes.  
Although this method is more efficient than PCR-RFLP, it is more expensive and like 
with any emerging new technologies sometimes available technical support is scarce. 
Sobrino et al reviewed other SNP genotyping discrimination assays (such as allele 
specific hybridization, primer extension methods) and detection methodologies 
(fluorescence arrays, mass spectrometry and luminescence) that could be used in addition 
to the two that were explored in this study (2005).  The Matrix-Assisted Laser 
Desorption/Ionization Time-Of-Flight (MALDI-TOF) mass spectrometry has become 
one of the better tools for SNP genotyping (Tost and Gut, 2005; Pusch et al., 2002; Bray 
et al., 2001).  Mass spectrometry detection of single-base extension, such as Sequenom 
MassARRAY platform (Gabriel et al., 2009) could possibly be an alternative for the 
sequencer-based approaches such as SNuPe for lower-throughput assays with fewer loci.  
In addition, High-throughput genotyping platforms based on Affymetrix GeneChip or 
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Illumina’s Beadchip are becoming the standard for high-throughput assays of genome-
wide marker sets (Ragoussis, 2009).  The optimization and the advancement of 
methodologies are essential considerations when selecting a genotyping method for a 
genetic association study. Efficient genotyping is as important as the marker selection 
because unreliable genotype calls may lead to spurious results in association studies. 
 
Linkage Disequilibrium Patterns 
 In part to test whether sparse sampling of SNPs contributes to inconsistent 
detection of potentially causative genetic variants among human populations (CEU, YRI 
and CHB+JPT), we used three or fewer SNPs per gene to evaluate the LD (r2) patterns on 
the two genes.  Using ≤ 3 SNPs per gene did not permit this evaluation, but our reasons 
also included costs and technical limitations (i.e. the unavailability of restriction enzymes 
for recognizing many sites), as mentioned above.  We found that some SNPs show poor 
association with the assayed SNPs (Tables 9, 10 and 11) on the both of the genes, but 
more predominantly observed in the SLC6A3/DAT1 gene (either using 2 or 3 tag SNPs, 
Table 11).  In the COMT gene, the majorities of the captured SNPs had the strongest LD 
(r2) with the tag SNPs (0.71-0.8) in the CEU population and lower in the YRI (0-0.1) and 
the CHB+JPT (0.31-0.4) populations.  In the DAT1/SLC6A3 gene (using three tag SNPs), 
the majority of the SNPs (15) had a low r2 (0-0.1), but there were also as many SNPs (14) 
that showed strong LD (0.91-1) with the tag SNPs in the CEU population; the YRI 
population captured SNPs showed significantly lower r2 values (0-0.1). The use of only 
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two tag SNPs in the DAT1/SCL6A3 gene showed an average low r2 of the captured SNPs 
on the three populations (CEU=0.11-0.1; YRI=0-0.1; CHB+JPT=0-0.02).   Furthermore, 
we observed that r2 can be close to 1 only when MAFs are similar, though SNPs with 
similar MAFs could have very low r2.  Our results could suggest that sparse sampling of 
tag SNPs in these genes (COMT and SLC6A3) does not capture the other SNPs well and 
that a denser set of tag SNPs is needed. 
The common-disease common-variant (CDCV) hypothesis suggests that causative 
SNPs are common.  Thus, under this hypothesis, common tag SNPs should capture the 
disease risk associated with causative SNPs most efficiently.  We hypothesized that 
potentially causative uncommon SNPs are captured more poorly by common tag SNPs, 
thus making the efficacy of association studies as usually designed dependent on the 
validity of the CDCV hypothesis.  We evaluated this (using our sparse tag SNP selection) 
by doing a regression of SNP-tag set r2 values on MAF for each gene, with the 
expectation that the regression coefficient will be significantly positive.  On the COMT 
gene, the three populations showed similar trend of regression (with positive slopes), but 
only the CEU population showed significance (p=0.048).  This is partly because we 
selected the tag SNPs accordingly to the MAF on the CEU and therefore LDs were better 
captured on this population (Figure 14). Consequently, on the SLC6A3/DAT1 gene (using 
3 tag SNPs), the CEU and YRI population showed similar trends of regression with 
positive slopes and of significance (p=0.006, p=0.001 respectively; Figure 15).  On the 
other hand, no significant changes on the regression using 2 tag SNPs on the CEU and 
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YRI populations in this gene.  The CHB+JPT population showed significance using 2 tag 
SNPs but with a negative slope (Figure 16).  The regression results suggest that there is a 
trend toward poorer capturing of rare SNPs, which would mean lesser detection of 
AD/HD associations if rare SNPs were causative.  The non-significant regression results 
on the SLC6A3/DAT1 (2 tag SNPs) gene may be due to the relatively low frequency of 
the two tag SNPs especially in the CHB+JPT populations and causing the slope to be 
negative.  Our results could also suggest that 3 tag SNPs is better than 2 tag SNPs in 
capturing LD on these genes particularly the SLC6A3/DAT1 gene.  However, our method 
does not represent a true haplotype analysis because we selected the tag SNP having the 
greatest LD with each captured SNP on these genes and used one reference population to 
select our tag SNPs. Thus, in support with our results on the previous paragraph, a denser 
SNP and/or haplotype-based tag SNPs is suggested to further test our hypothesis. 
 The LD (r2) comparison of each identified SNPs between the tag SNP sets in the 
CEU population with that in the other two populations predicted that the tag SNPs 
selected are less useful in the other populations.  Our results showed on average that the 
LD (r2) values between the tag SNPs and captured SNPs for COMT and SLC6A3/DAT1 
genes were lower in the YRI and CHB+JPT populations compared to the CEU population 
(Tables 9, 10, and 11) and their LD distributions amongst populations were variable 
(Figures 11,12, and 13).  Overall, the Wilcoxon Sign Test (one-tailed) showed significant 
differences in the mean r2 values between CEU and the other two populations (lower) on 
these two genes.  We expected these results because the tag SNPs were chosen according 
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to the MAF patterns on the CEU population to capture LD on these genes; and the tag 
SNPs may not do as well in the other populations for which they were not evaluated 
ahead of time. The significant reductions of the r2 in the other two populations relative to 
the CEU would support that associations on these genes varies on between populations 
and suggest that prior assessment of tag SNPs using the HapMap is a essential step in the 
design of genetic association studies.  This will help tailor the tag SNP for a specific 
population sample as LD patterns may vary among the human populations. 
It is estimated that there are about 7 million of SNPs with MAF of at least 5% 
across the entire human population (Kruglyak and Nickerson, 2001).  They are known to 
contribute to the population diversity and phenotypic differences between individuals and 
their predispositions to diseases.  Linkage disequilibrium in human populations has been 
influenced by factors affecting human evolution (Goldstein and Weale, 2001).  Studies by 
Kruglyak et al (1999) concluded that LD would not extend beyond 3kb, but populations 
that have undergone severe genetic bottlenecks and recent admixture have resulted in 
extended regions of LD (Wilson and Goldstein, 2000).  LD also deteriorates rapidly as 
the distance between markers increases in population of unrelated individuals (Orr and 
Chanock, 2008).  Currently, there are no explanations on the regulation on the size of 
haplotype block boundaries, but the size and distribution of haplotype blocks are variable 
between populations (The International HapMap Consortium, 2005; Reich et al., 2001; 
Conrad et al., 2006).  As a general assumption, the average block size in African 
populations is smaller than for the other populations studied (European Caucasians or 
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East Asians (Orr and Chanock, 2008); this is also evident with the LD pattern results on 
the COMT gene on these populations (Figure 17).   
 The considerations above suggest that population-specific markers may be 
needed for genetic association studies, and our results (r2 and MAF regression analyses) 
support this idea.  Ideally for genetic association studies, an investigator can select one of 
the four populations that is representative or demographically similar to their population 
samples and test the transferability of the (HapMap population) SNPs (tag SNPs) to their 
population sample.  Mueller et al surveyed the linkage disequilibrium patterns and 
tagSNP transferability on their European sample population (randomly chosen with no 
specific diagnosis) and used the CEU population as their reference to select tag SNPs.  
They scanned four genomic regions (749 kb total) containing candidate genes for 
complex traits.  In the two regions analyzed, the LD patterns of sets of tag SNPs that 
were selected from CEU population performed well or transferable to their sample 
population (2005).  On the other hand, a study comparing the performance of HapMap 
SNP data with  their  sample population (Shanghai Chinese)  found that tag SNPs on the 
CHB population on the HapMap data had better correlation with their sample group 
compared to the other populations on the HapMap database looking at chromosome 
1q21-q25 (Hu et al,  2008).  Both of these studies used the performance of HapMap-
derived tag SNPs in their sample population study using a denser set of SNP tags.  These 
studies (Mueller et al, 2005; Hu et al, 2008) further support that demographics can affect 
LD patterns and provide suggestions for ways on how the HapMap database could be 
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utilized.  In addition, our study also supports that LD is affected by demography and it is 
important to consider when selecting populations for future genetic studies of AD/HD on 
these candidate genes.  Consequently, the three populations on the HapMap database do 
not represent all the human populations and perhaps it could extend its population group 
as reference for future association studies on different populations. 
  
General Suggestions and Recommendations 
In this current study, we have addressed some of the essential issues (molecular 
assays and human variation patterns) that may explain the inconsistent results of AD/HD 
association studies in the current literature and may assist in the design of any genetic 
association studies based on linkage disequilibrium.  The International HapMap Project is 
continually generating genome-wide and densely spaced sequence variation data in 
different human populations (The International HapMap Consortium, 2005).  This type of 
data will help in the design of LD-based genetic association studies and it will promote 
multi-locus LD measures to assess the variability of background correlation across the 
genome (Mueller, 2004).  The prior assessment of markers, particularly SNPs, using this 
data and other software such as Haploview will better inform an investigator on the 
selection of markers for their particular study.  We recommend the selection of a denser 
tag SNPs (more than 3) and/or using 2-3 tag SNPs per haplotype blocks rather than what 
we used in this study, selecting the best SNPs (2-3 tag SNPs) to cover the gene region.  
Currently, genetic association studies on the candidate genes and genome-wide scans  
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involving the monoamine system (dopamine, serotonin and norepinephrine) on AD/HD  
are using high-density tag SNP and hapolotype-based LD SNP selection however, their 
results are still inconclusive (Guan et al., 2009;  Elia et al., 2009; Kollins et al, 2008;  
Ouelle-Morin et al, 2007).  Recently, Elia et al (2009) had identified common inherited 
copy variations (CNVs) in their AD/HD probands relative to their controls in genes 
associated with neurodevelopmental pathways and disorder. This is the first study in 
AD/HD that showed a potential role of CNVs and also suggested other potential 
candidate genes such as PTPRD (protein tyrosine phosphatase receptor type D) and 
GRM5 (Glutamate receptor 5) for further study. 
The Illumina Infinium (Illumina, Inc., San Diego, CA) genotyping platform 
seems to be the choice for SNP genotyping assays with large sample populations 
(Guan et al., 2009; Kollins et al, 2008).  A thorough testing of new SNP genotyping 
technologies is essential as false genotyping calls can results to spurious association 
results.  We have suggested several technologies that are currently available (SNP 
genotyping section) and we recommend selecting a technology that has a reliable 
technical support.  Our analysis of r2 between the tag SNPs and captured SNPs using the 
best individual SNPs on each of the genes may not be the best approach to capture LD; 
rather a true haplotype-based approach might be better in capturing the LD patterns on 
these genes and also extending the tag SNPs for more coverage will be helpful.   
Furthermore, there are also other methods for estimating and testing of LD.  In this 
project we have used a Pairwise LD method using the Haploview program by selecting a 
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sparse set of tag SNPs based on the best MAF and did not select tag SNPs based on 
haplotype blocks.  Since SNPs can arise on independent haplotypic backgrounds and that 
many common haplotypes exist at a given locus (Orr and Channock, 2008), a SNP 
haplotype-based method is a complementary alternative of selecting SNPs (Stram, 2004).  
The use of haplotype-tagging SNP allows a researcher to examine multiple independent 
SNPs across the gene rather than focusing on a specific repetitive SNP on a gene.  This 
provides a more thorough examination on how variation in specific genes may be 
associated with the specific phenotypes (Kollins et al., 2008).  The LD patterns are very 
important in for the design and interpretation of association studies (Mueller, 2004) and 
there are a variety of LD measures available online in addition to the Haploview that can 
be used for estimating and testing for LD (Genetix, http://www.univ-
montp2.fr/%7Egenetix/genetix/genetix.htm; DNaSP, http://www.ub.es/dnasp/; The R 
Project for Statistical Computing, http://www.r-project.org/ are few of the websites 
available).  In addition, other programs such as WCLUSTAG are being developed by 
combining functional and linkage disequilibrium information in the selection of tag SNPs 
in order to prioritize the SNPs being genotyped (Sham et al., 2007). 
The common-disease common-variant hypothesis states that the genetic 
variation underlying susceptibility to common heritable disease/trait existed within the 
founding population of contemporary human population and that these genetic variants 
have escaped selective pressure and have small to modest effect on the disease/trait 
(Doris, 2002;  Chen et al., 2006; Collins et al., 1999; Risch and Merikangas, 1996; 
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Lander, 1996).  Understanding the forces that drive and shape human genetic variations 
are important considerations in LD-based genetic association studies.  As we have shown 
in this study, LD varies between populations; it is affected by evolutionary forces such as 
bottlenecks and varies based on the populations’ demographics (Goldstein and Weale, 
2001; Kruglyak et al, 1999; Wilson et al., 2000 Orr and Chanock, 2008; Mueller et al, 
2005; Hu et al, 2008).  LD patterns are sufficiently consistent to allow efficient 
representation of common variation with the use of tag SNPs.  However, association 
studies based on CDCV hypothesis has been criticized for not fully explain the genetic 
component of many diseases (such as the inconsistent results on AD/HD).  Perhaps we 
have reached a plateau where there are no more common variants to discover or no more 
that are worth discovering and we need to turn our focus on rare variants (Goldstein, 
2009;  Iyengar and Elston, 2007).  The variability of the LD patterns observed in our 
results (i.e. MAF and r2 regressions) deviate from the CDCV hypothesis and may suggest 
that different strategy for selecting tag SNPs may be needed to further study the 
association of these genes with AD/HD. 
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